Nuvation Bio 2026 Quarterly Mix for $150M IBTROZI Revenue

Analysis of the 2026 Quarterly Mix Assumption for IBTROZI First-Line vs. Later-Line Patients to Reach $150M Consensus Revenue

---

Summary of Relevant Data Points:

1. New Patient Starts and Mix (2025 Data & Early 2026 Trends)

   • By end of 2025, 432 new patients started IBTROZI.
   • Quarterly run rate of ~200 new patient starts (NPS) in 2H 2025, continuing into 2026.
   • Majority of these new patient starts currently are later-line patients (3rd line plus), but first-line patient starts are steadily increasing.
   • Approximately 75% of treatment discontinuations come from later-line patients, reflecting shorter durations on therapy in this group.
   • First-line (TKI-naive) patients experience a much longer median duration of response (DOR) of ~50 months, compared with later-line patients who discontinue quickly.
   • The total pool of later-line TKI-experienced patients in the US is estimated at about 1,000 patients, and a significant majority of these patients have already been captured as IBTROZI users.
   • Growth in patient starts beyond this pool is expected to come predominantly from first-line patients, who will stay on therapy longer, driving sustained revenue growth.

2. Revenue and Duration Dynamics

   • 2025 U.S. net product revenue: $24.7M.
   • Q4 2025 IBTROZI U.S. net product revenue: $15.7M.
   • Total 2025 revenue (including milestones and royalties): $62.9M.
   • Gross-to-net discount around 25% and likely to increase slightly before stabilizing.
   • The revenue gap between new patient starts and net product revenue reflects the short duration of therapy among later-line patients.
   • Revenues are expected to "catch up" over a few quarters as first-line patient mix grows, due to longer persistence on therapy.

3. Revenue Assumptions for 2026

   • Analysts' consensus revenue estimate for IBTROZI is $150M for 2026.
   • Management expects steady new patient start rates (~200+ per quarter).
   • The transition from later-line predominant mix to increasing first-line exposure will drive revenue stacking.
   • Revenue build-up is expected to gradually materialize over 2026 as first-line patients accumulate on therapy.
   • Pricing and reimbursement landscape appears stable with gross-to-net discounts in the 25-30% range.

---

Quantitative Mix and Revenue Assumptions to Reach $150M Revenue in 2026

To estimate a quarterly mix assumption required to reach ~$150M consensus revenue in 2026, consider:

---

Step 1: Estimate Average Quarterly Revenue per Patient

• Q4 2025 net revenue: $15.7M.
• Number of new patients started in Q4 2025: 216 ¹¹³.
• Because patients started during the quarter generate less than a full quarter's revenue, actual average revenue likely comes from cumulative active patients including prior quarters.
• Assume:
  • ~75% of patients are later line in early launch.
  • Later-line patients remain on therapy for ~1 month (~1/3 of a quarter).
  • First-line patients remain on therapy longer (for calculation convenience, we treat later line as 1 month quarter equivalence, first line as 4 full quarters initially).

---

Step 2: Approximate Revenue Contribution by Line

Define variables:

• ( x ) = proportion of first-line patients in 2026
• ( 1 - x ) = proportion of later-line patients in 2026

Assumptions:

• Later-line average treatment duration per quarter per patient: ~0.33 quarter
• First-line average treatment duration per quarter per patient: close to full quarter (due to long DOR)
• Per-patient quarterly revenue (net of discounts): Let ( R )

Then total quarterly revenue ( Q ) can be approximated as:

[ Q = N \times R \times (x \times 1 + (1-x) \times 0.33) ]

Where ( N ) = total active patients in that quarter.

---

Step 3: Estimating Active Patient Base and Revenue Growth

• With 200 new patient starts per quarter, initial quarters heavily later line, ( x \approx 0.2 ).
• Over the year, ( x ) increases to reflect transition to first-line.
• Let's assume the quarterly increase in first-line share:

---

Step 4: Aggregate Quarterly Revenue to Hit $150M Annual Estimate

• Using Q4 2025 data as a base:

  • ( 200 ) patient starts (approximate),
  • Net revenue $15.7M with majority later line.

• Each later-line patient contributes roughly 1/3 revenue fraction of a first-line patient.

• To reach $150M annually, average quarterly revenue must be about:

[ \frac{150M}{4} = 37.5M \text{ per quarter} ]

• This implies revenue growth of approximately 2.4x from Q4 2025 baseline.

---

Step 5: Modeling Quarterly Revenues with Increasing First-Line Mix

Calculate quarterly revenue as function of ( x ):

[ Q = 200 \times R \times (x + 0.33(1-x)) = 200 \times R \times (0.33 + 0.67x) ]

At Q4 2025 (mostly later line), ( x \approx 0.2 ), revenue = $15.7M:

[ 15.7M = 200 \times R \times (0.33 + 0.67 \times 0.2) = 200 \times R \times (0.33 + 0.134) = 200 \times R \times 0.464 ]

Hence,

[ R = \frac{15.7M}{200 \times 0.464} = \frac{15.7M}{92.8} \approx 169,274 \text{ per full quarter net revenue per fully treated (first-line equivalent) patient} ]

---

Step 6: Quarterly Revenue Forecast with Increasing First-Line Mix

Calculate revenue per quarter for assumed first-line proportions:

---

Step 7: Adjust for Build-up of Active Patient Pool Over Multiple Quarters

• First-line patients persist for multiple quarters, compounding active patient count.
• The above calculation assumes only new starts per quarter contributing revenue; but due to long DOR, first-line patients started in Q1 will continue generating revenue Q2/Q3/Q4 and beyond.
• Later-line patients have short duration, so minimal carryover.
• To approximate stacking effect:

Assuming first-line patients contribute revenue for 4 quarters on average, later-line for only 1 quarter:

Calculate active patients per quarter (starting Q1 2026) with quarterly 200 patient starts and previously started patients still active:

• Later-line active patients = new later line starts per quarter × 1
• First-line active patients = sum of first-line starts past 4 quarters

Assuming gradual shift of starts to first line as above, let’s simplify:

---

Step 8: Calculate Quarterly Revenue with Stacked Population

Use per patient quarterly revenue (first-line full $169,274; later-line 1/3 = $56,425):

---

Step 9: Interpretation

• Under reasonable assumptions, achieving $150M in 2026 revenue requires a gradual shift of first-line patient starts from 20% in early 2026 to 65% by year-end.
• New patient starts remain roughly stable at ~200 per quarter. The transition in mix and strong persistence on therapy in first-line patients drives the revenue stacking.
• Revenue growth is expected to accelerate in back half of 2026 as accumulated first-line patients sustain revenue.
• This aligns with management’s commentary about capturing the later-line population early and growing first-line penetration in 2026 driving durable revenue growth ⁵¹⁷²⁴.
• Gross-to-net adjustments (around 25%-30%) are built into the per-patient revenue estimates based on net product revenue reported ⁹¹⁰.
• Seasonality and payer dynamics may cause quarter-to-quarter fluctuations but overall trend supports meeting consensus revenue.

---

Final Quantitative Quarterly Mix Assumption for 2026 to Reach $150M Consensus Revenue

---

Conclusion

To achieve $150 million consensus revenue for IBTROZI in 2026, Nuvation Bio’s launch trajectory implies:

• Maintaining a steady total new patient start rate of ~200 per quarter.
• Transitioning quarterly new patient starts share from predominantly (~80%) later-line patients in early 2026 to a majority (~65%) first-line patients by year-end.
• Leveraging the long duration of response (~50 months) in first-line patients to multiply cumulative active patients and revenue.
• Sustaining later-line patient treatment with high discontinuation (~75%), contributing short-term but important near-term revenue.
• This mix ramp-up drives the required revenue stacking despite the initial latency between patient starts and revenue recognition.

This quantitative assumption aligns well with management’s commentary on launch dynamics, patient mix, and revenue growth pacing ⁵¹⁷²⁴.

---

Note: The analysis incorporates assumptions derived from reported new patient starts, clinical durations, revenue figures, and management guidance from the 2025-Q4 earnings transcript of Nuvation Bio Inc. It serves as a model to connect patient mix dynamics with revenue projections toward meeting consensus estimates.